PT - JOURNAL ARTICLE AU - Regina M. Sullivan AU - Michael Stone AU - John F. Marshall AU - Florian Uberall AU - Susan A. Rotenberg TI - Photo-Induced Inactivation of Protein Kinase Cα by Dequalinium Inhibits Motility of Murine Melanoma Cells AID - 10.1124/mol.58.4.729 DP - 2000 Oct 01 TA - Molecular Pharmacology PG - 729--737 VI - 58 IP - 4 4099 - http://molpharm.aspetjournals.org/content/58/4/729.short 4100 - http://molpharm.aspetjournals.org/content/58/4/729.full SO - Mol Pharmacol2000 Oct 01; 58 AB - Dequalinium (DECA) is a potent antitumor agent and inhibitor of protein kinase C (PKC). Previously it was shown that PKCα activity in vitro could be irreversibly inhibited when treated with DECA at low micromolar concentrations and irradiated with 366 nm of light. This approach was used to probe the role of intracellular PKC activity in the motility of metastatic murine melanoma B16 F10 cells and as a target for DECA analogs with increasing PKC inhibitory potencies. Pretreatment of a monolayer of B16 F10 cells with 250 nM of a DECA analog in the presence of UV irradiation for 5 min resulted in 1) complete inhibition of cell motility for up to 4 h in a time-lapse motility assay and 40 to 60% inhibition of cell migration in a Boyden chamber, and 2) inhibition by 40 to 60% of intracellular phosphatidylserine/Ca2+-dependent PKC catalytic activity, signifying inactivation of a conventional PKC isoform. Because PKCα is the only conventional PKC isoform detected in B16 F10 cells, a stably transfected clone expressing a kinase-defective mutant of PKCα was developed that exhibited a substantial loss of adhesion and motility and was refractory to further inhibition by DECA. These findings identify PKCα catalytic activity both as a mechanistic component of cell motility and adhesion and as a critical intracellular target of DECA. These studies further suggest that the combined use of UV with nanomolar concentrations of DECA offers an effective chemotherapeutic approach to inhibit metastatic behavior of melanoma cells.